This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Newsramp
newsramp.com
did:plc:xlsujlrwr5xpfxgaf4pixhri
VERAXA Biotech (NASDAQ: VRXA) advances its bispecific ADC program VXA-222 after OmniAb completes antibody discovery work. The 'AND-gate' molecule targets two tumor antigens to improve precision in solid tumor treatment. #Biotech #Oncology
2026-07-27T17:03:14.874Z